Contains Nonbinding Recommendations

**Guidance on Hydrochlorothiazide; Triamterene**

This guidance represents the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Hydrochlorothiazide; Triamterene

**Dosage Form; Route:** Capsules; oral

**Recommended Studies:** Two studies

1. Type of study: Fasting
   - Design: Single-dose, two-way, crossover in vivo
   - Strength: 25 mg/50 mg
   - Subjects: Healthy males and non-pregnant, non-lactating females, general population
   - Additional comments: Female subjects should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.

2. Type of study: Fed
   - Design: Single-dose, two-way, crossover in vivo
   - Strength: 25 mg/50 mg
   - Subjects: Healthy males and non-pregnant, non-lactating females, general population
   - Additional comments: See comments above.

**Analytes to measure:** Hydrochlorothiazide and triamterene in plasma

**Bioequivalence based on (90% CI):** Hydrochlorothiazide and triamterene

**Waiver request of in-vivo testing:** 25 mg/37.5 mg strength based on (1) acceptable bioequivalence studies on the 25 mg/50 mg strength; (2) proportional similarity across all strengths and (3) acceptable dissolution testing on all strengths.

Hydrochlorothiazide/Triamterene, 25mg/37.5 mg and 25 mg/50 mg, are the subject of two separate reference products, two separate applications must be submitted for each strength. You may request a waiver of in vivo bioequivalence testing for the 25 mg/37.5 mg strengths if you meet the criteria. Please cross-reference the in-vivo studies conducted on the higher strength along with your waiver request. Please refer to the Guidance for Industry, Variations in Drug Products that May Be Included in a Single ANDA located at:


**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website, available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and

Finalized Aug 2017
reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).